Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Report Date: December 31, 2018
Event: Entry into a Material Definitive Agreement (Eighth Amendment to Credit Agreement).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, or total debt levels. The report focuses exclusively on the structural modification of the company's credit facility.
Material Changes
- Term Loan Commitments: Reduced to zero under the Eighth Amendment to the Credit Agreement dated March 21, 2017.
- Covenant Testing Date: Extended to January 31, 2019.
- Parties Involved: Organogenesis Inc. and Prime Merger Sub, LLC (subsidiaries) with Silicon Valley Bank as administrative agent.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk disclosures beyond the description of the credit agreement amendment. The extension of the financial covenant testing date suggests a need for additional time to meet financial requirements, though the filing does not explicitly state the company's current compliance status.
Investor Verification Checklist
- Verify the current outstanding balance of the credit facility following the reduction of term loan commitments to zero.
- Confirm whether the company met the financial covenants as of the new testing date (January 31, 2019).
- Review the full text of Exhibit 10.1 (Eighth Amendment) for any additional conditions or fees associated with the amendment.
- Check subsequent filings for any further amendments or defaults related to the Credit Agreement.